Prostate Cancer Clinical Trial: ARN-509
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Prostate Cancer Clinical Trial: ARN-509
- March 1, 2015
- 2 min read
A Phase III clinical trial is underway using ARN-509, a second-generation anti-androgen agent, for patients with previously untreated prostate cancer. This study specifically targets high-risk patients with non-metastatic prostate cancer who have a rapidly increasing PSA level (PSA doubling time of 10 months or less). The trial evaluates the efficacy and safety of the drug compared to a placebo.
Eligibility Criteria:
- Patients aged 18 years or older.
- Confirmed diagnosis of prostate cancer.
- High risk of metastasis (PSA doubling time ≤ 10 months).
- PSA levels continuing to rise (> 2 ng/mL) despite androgen deprivation therapy (ADT).
For more details, visit: Clinical Trials JP
Drug Description: Androgen Receptor Antagonist ARN-509
A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. Ultimately, this inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.
Trial Period: March 1, 2015 – December 31, 2016
#ProstateCancer #ClinicalTrial #ARN509 #Apalutamide #AntiAndrogen #CancerResearch
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4